Compare ETON & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETON | BNTC |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 344.4M |
| IPO Year | 2018 | 2020 |
| Metric | ETON | BNTC |
|---|---|---|
| Price | $62.50 | $9.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $80.75 | $23.29 |
| AVG Volume (30 Days) | ★ 497.6K | 177.7K |
| Earning Date | 11-05-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $79,950,000.00 | N/A |
| Revenue This Year | $125.03 | N/A |
| Revenue Next Year | $59.47 | N/A |
| P/E Ratio | $46.82 | ★ N/A |
| Revenue Growth | ★ 104.94 | N/A |
| 52 Week Low | $14.27 | $7.89 |
| 52 Week High | $70.64 | $14.39 |
| Indicator | ETON | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 49.46 |
| Support Level | $48.06 | $8.14 |
| Resistance Level | $66.37 | $9.29 |
| Average True Range (ATR) | 4.03 | 0.64 |
| MACD | 1.88 | 0.16 |
| Stochastic Oscillator | 65.54 | 53.62 |
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.